Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial
RTTNews
|
113 days ago
(RTTNews) - Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.
read more
AstraZeneca Says AIRSUPRA Now Commercially Available In US As FDA-approved Option For Asthma
AstraZeneca (AZN, AZN.L) announces Monday that AIRSUPRA (albuterol/budesonide) is now commercially available in the US by prescription. AIRSUPRA was approved based on the results from two Phase III trials, MANDALA and DENALI.
RTTNews
|
99 days ago
Allorion Therapeutic Inks Agreement With AstraZeneca For EGFR L858R Allosteric Inhibitor Program
Allorion Therapeutics, a US and China-based biotechnology company, on Tuesday entered into an exclusive option and global license agreement with British drug major AstraZeneca plc (AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
RTTNews
|
119 days ago
Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program
Gilead Sciences, Inc. (GILD) announced Tuesday an agreement with Holon, Israel-based cancer immunotherapy company Compugen Ltd. (CGEN) to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.
RTTNews
|
133 days ago
AstraZeneca Files Legal Challenge To Protect Access To Medicines For Cancer And Rare Diseases
AstraZeneca plc (AZN) said Friday it has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA) to help protect access to medicines for cancer and rare disease patients.
RTTNews
|
249 days ago
AstraZeneca Q2 Profit Surges, Signs Gene Therapy Deal With Pfizer; Stock Up
Shares of AstraZeneca Plc were gaining around 4 percent in London trading as well as around 5 percent in pre-market activity on Nasdaq after the British drug major reported Friday significantly higher profit for its second quarter. Top line beat market estimates. Further, the company maintained its outlook for fiscal 2023, expecting growth. In addition, AstraZeneca noted that its Rare Disease ...
RTTNews
|
277 days ago
AstraZeneca Partners Vanguard Renewables To Use Renewable Natural Gas In The U.S. By End Of 2026
In a first-of-its-kind collaboration, British drug major AstraZeneca plc (AZN, AZN.L) is partnering with Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of its sites in the United States by the end of 2026.
RTTNews
|
322 days ago
BioLight Inks Agreement With Alexion To Explore Technology For Diagnosis Of Retinal Diseases
BioLight Life Sciences Ltd. announced Tuesday it has signed a research collaboration agreement with Alexion Pharmaceuticals, Inc. (ALXN), a subsidiary of AstraZeneca plc (AZN, AZN.L), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases.
RTTNews
|
336 days ago
AIM ImmunoTech Inks Pancreatic Cancer Clinical Research Deals With AstraZeneca, Erasmus
Immuno-pharma company AIM ImmunoTech Inc. (AIM) announced Tuesday it has entered into an external sponsored collaborative clinical research agreement with Netherland-based Erasmus University Medical Center and AstraZeneca plc. (AZN, AZN.L).
RTTNews
|
469 days ago